Title : Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial.

Pub. Date : 2022 May 20

PMID : 35595817






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints. Paclitaxel CD44 molecule (Indian blood group) Homo sapiens
2 This is the first study to identify VSNL1 and CD44 RNA expression levels as biomarkers for selecting GC patients that are likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy. Paclitaxel CD44 molecule (Indian blood group) Homo sapiens